FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
Lotimatou avorago bare								
hours per response:	0.5							
p soponoo.	0.0							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Schenkein David P  (Last) (First) (Middle)  C/O AGIOS PHARMACEUTICALS, INC.  38 SIDNEY STREET, 2ND FLOOR				AG: 3. D 05/	2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [ AGIO ]  3. Date of Earliest Transaction (Month/Day/Year) 05/11/2015  4. If Amendment, Date of Original Filed (Month/Day/Year)							r) 6	. Relationship of Reporting In Check all applicable)  X Director  X Officer (give title below)  Chief Executi  Individual or Joint/Group Fine)				10% 0 Other below	Owner (specify
(Street)  CAMBR  (City)			2139 Zip)										X					
		Tabl	e I - Non-Deriv	ative	Secu	ırities	Ac	quire	d, D	isposed o	f, or E	Benefici	ally	Owne	ed			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Ye	Execution if any		on Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)			ıd	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
					С	ode	v	Amount	(A) or (D)	Price		Report Transa			,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
Common	05/11/201	5						3,107	D	\$110.01 <sup>(2)</sup>		96,794			I	See footnote <sup>(3)</sup>		
Common stock			05/12/201	5				S <sup>(1)</sup>		2,093	D	D \$110.03 <sup>(4</sup>		94,701			I	See footnote <sup>(3)</sup>
Common stock														238,772				See footnote <sup>(5)</sup>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		action (Instr.	5. Nun of Deriva Securi Acqui (A) or Dispo of (D) (Instr. and 5)	tive ties red sed	Expiration (Month/Daged d		Expiration	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares		of De See (In:	Price 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)		у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## Explanation of Responses:

- 1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$110.00 to \$110.12. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 3. Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- 4. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$110.00 to \$110.20. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 5. Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.

## Remarks:

/s/ Glenn Goddard, as Attorney-in-Fact for David 05/1 Schenkein

05/13/2015

CHERKEIII

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.